IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding Board meeting held on August 07, 2025.

Strategic Transactions View source PDF Explain this filing

IOLCP · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.3%Reaction day

₹94.66

prior close

₹98.09

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.3%+4.6% vs market

Pharmaceuticals peers, median of 148sector+0.2%+4.0% vs sector

On the reaction day the stock moved 4.6 pts more than Nifty Microcap 250 and 4.0 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

-0.1

15m

-0.9

30m

-0.5

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.3-0.3+4.6+0.2+4.0

Next day

-2.8-1.2-1.7-0.3-2.5

-4.4-1.0-3.4-0.2-4.2

-4.6-1.0-3.6-0.1-4.5

-1.6-0.3-1.3+0.3-1.9

-2.8-1.1-1.7-0.6-2.3

+2.9+1.6+1.3+0.2+2.7

15d

-1.2-0.2-1.0-1.2-0.1

+17.5+1.4+16.1-0.9+18.4

+7.3+0.2+7.2-0.9+8.2

-3.4+0.9-4.3-3.7+0.3

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 148Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

IOL Chemicals and Pharmaceuticals reported its Q1 FY26 (quarter ended 30 June 2025) unaudited results, with revenue from operations rising to Rs. 551.69 crore from Rs. 502.38 crore a year earlier, a growth of about 9.8%. Profit after tax grew to Rs. 33.96 crore (vs Rs. 29.68 crore) and EPS came in at Rs. 1.16 (vs Rs. 1.01). The pharmaceutical segment contributed Rs. 329.33 crore in revenue while chemicals contributed Rs. 281.06 crore. The board also approved setting up a wholly owned subsidiary in the United Kingdom to expand into the UK and EU markets. Additionally, the company will set up a new Unit 9B dedicated to manufacturing Minoxidil and its intermediates with 120 MTPA capacity, involving a small capex of Rs. 5.50 crore to be funded through internal accruals and expected to be completed by December 2025.

Likely market impact

Steady double-digit profit growth and a clean quarterly beat support a positive view for shareholders. The UK subsidiary and the Minoxidil expansion signal the company's push to scale globally and strengthen its pharma API portfolio, though the Rs. 5.5 crore capex is small and unlikely to materially move the stock on its own.